SeLux Diagnostics, Inc.

SeLux’s Next Generation Phenotyping (NGP) platform provides rapid, high-throughput, fully-automated AST results, enabling same-shift susceptibility testing of up to 50 antibiotics in parallel. The platform is driven by SeLux’s proprietary assay, which differentiates antibiotic-induced bacterial growth modes with a surface-binding fluorescent amplifier.

Address
Charlestown, MA 02129
United States
Telephone

+1-617-945-9383

Microbiology Product Areas

Clinical

Antibiotic Resistance Show all suppliers
Antibiotic Sensitivity Show all suppliers
Antimicrobial Resistance (AMR) Show all suppliers